Waterhouse 95
ctla4 ko
Leach 96
anti ctla ab tumour rej
hodi 2010
pIII antictla4 ab plateau
robert 11
I+D or D+P pIII trial
Robert 15
N vs D
Larkin 2015
Alexandrov 13
TMB
Snyder 2014
high fitness neoantigens
Marabelle 2020
clin trial high tmb = high survival
Gurajao 2020
preprint
small no. tumour types and wrong FDA cut-off
Le 2015
MMRd
Zaretsky 2016
specific jak mutations
Chowell 2018
pt germline gen
HLA-I het
ttopalian 2012
PD1 ex as pred of pt resp
Sunshine and Taube 2015
PD1 not a good marker
Tumeh 2014
TIL densty
De Henau 2016
MDSCs and Pi3Ky inhibitors
Matson 2018
microbiota
Papadopoulos 2019
LAG-3
Ribas 2017
oncolytic virus
Valero 20211
N:L ratio
ctla4 ko
Waterhouse 95
anti ctla ab tumour rej
Leach 96